Disease Landscape and Forecast Insights

DRG estimates that 60% of epilepsy patients experience partial-onset seizures (POS). More than two dozen antiepileptic drugs (AEDs) are available in the United States and Europe—the majority of…

DRG estimates that 60% of epilepsy patients experience partial-onset seizures (POS). More than two dozen antiepileptic drugs (AEDs) are available in the United States and Europe—the majority of…

Atrial fibrillation (AF) is the most commonly encountered, sustained cardiac arrhythmia and a condition associated with extreme morbidity, mortality, and cost. The currently available AADs have…

Although the schizophrenia drug market is crowded, few, if any, effective therapies are available in the United States and Europe to treat the disease’s negative symptoms (e.g., blunted affect,…

The treatment paradigm for second- and subsequent-line advanced or metastatic colorectal cancer revolves around targeted agents (such as Erbitux, Vectibix, and Avastin) with or without…

Pediatric attention-deficit/hyperactivity disorder (ADHD) is a common childhood condition that can continue through adolescence and into adulthood. Despite a number of available—and largely…

Interstitial cystitis/bladder pain syndrome (ICBPS) is a disorder characterized by chronic pain, discomfort, and pressure in the pelvic region that often includes symptoms of urinary frequency and…

MARKET OUTLOOK The moderate to severe AD market is at the beginning of a revolution with the recent approval of the first targeted AD biologic, Sanofi/Regeneron’s Dupixent, and a promising…

Market Outlook Carbapenem-resistant organisms (CROs) are responsible for difficult-to-treat, life-threatening gram-negative infections that require hospitalization. Of the currently marketed…

IL-17 inhibitors have set a new efficacy standard in moderate to severe psoriasis, putting pressure on the more established TNF-α inhibitors and the IL-12/23 inhibitor Stelara. Although IL-17…

MARKET OUTLOOK Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide spectrum of clinical symptoms ranging from…

Rheumatoid arthritis (RA) treatment typically begins with one or more conventional DMARDs, followed by a first-line biologic, usually a TNF-α inhibitor. Patients refractory to one or more TNF-α…